New Service Breaks Down Brain Tumor Clinical Trial Barriers

Thousands of brain tumor patients across the UK are missing out on cutting-edge treatments simply because they don't know clinical trials exist for them.

The Brain Tumour Charity just launched Access to Clinical Trials for Brain Tumours (ACT-BT), a new service designed to fix a heartbreaking problem. Despite 578 clinical trials launching in 2024 alone, most patients never hear about opportunities that could help them.

The numbers tell a troubling story. Brain tumor clinical trials have the lowest recruitment rates of all cancer types in the UK, with just 12% of patients participating. A recent survey found that less than half of brain tumor patients were ever told about research opportunities by their doctors.

It's not that doctors don't care. Healthcare professionals want to connect patients with trials, but the NHS is stretched thin and tracking hundreds of ongoing studies with strict entry requirements is nearly impossible for busy clinicians.

ACT-BT solves this with a simple online referral system. Consultants can now quickly refer eligible patients to an expert panel that matches them with appropriate clinical trials happening across the country.

The charity is also busting common myths that keep patients from participating. Many people wrongly believe they'll receive dangerous untested drugs or ineffective placebos. In reality, most brain tumor trials test safe doses already established in earlier research or repurpose existing medications proven safe for other conditions.

Another myth: trials are only for patients out of options. Actually, trials test everything from prevention strategies to quality-of-life improvements, not just last-resort treatments. Some trials even welcome healthy volunteers for early-stage safety testing.

Geography matters too, but less than people think. While the charity acknowledges location-based inequalities exist, many trials operate at multiple hospitals simultaneously and some reimburse travel expenses for participants willing to journey to specialized centers.

The Ripple Effect spreads far beyond individual patients. Every person who joins a clinical trial contributes invaluable data that brings researchers closer to kinder, better cures for brain tumors. Past participants made today's treatments possible, and current volunteers are paving the way for tomorrow's breakthroughs.

ACT-BT represents a fundamental shift from expecting desperate patients to hunt for trials themselves to proactively connecting them with hope. The service acknowledges that in a healthcare system running at breaking point, innovation sometimes means building new bridges between the care people need and the research that could provide it.

For the first time, brain tumor patients across the UK have a dedicated pathway to potentially life-changing treatments they didn't even know existed.